PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21072493-8	2011	Vitamin K2 further antagonized receptor activator of NF-kappaB (RANK) ligand (RANKL)-induced NF-kappaB activation in osteoclast precursors.	Vitamin K 2	0-10	TNF superfamily member 11	Homo sapiens	78-83	
26267519-2	2015	Vitamin K2 groups (MK-4 and MK-7) were found to significantly inhibit RANKL-medicated osteoclast cell formation of bone marrow macrophages (BMMs) in a dose-dependent manner, without any evidence of cytotoxicity.	Vitamin K 2	0-10	TNF superfamily member 11	Homo sapiens	70-75	
15320745-5	2004	Furthermore, vitamin K2 also inhibits the expression of the osteoclast differentiation factor (ODF)/RANK ligand, tartrate-resistant acid phosphatase activity, and mononuclear cell formation, and induces osteoclast apoptosis in vitro.	Vitamin K 2	13-23	TNF superfamily member 11	Homo sapiens	60-93	
18260178-10	2008	CONCLUSION: Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL.	Vitamin K 2	12-18	TNF superfamily member 11	Homo sapiens	174-179	
15320745-5	2004	Furthermore, vitamin K2 also inhibits the expression of the osteoclast differentiation factor (ODF)/RANK ligand, tartrate-resistant acid phosphatase activity, and mononuclear cell formation, and induces osteoclast apoptosis in vitro.	Vitamin K 2	13-23	TNF superfamily member 11	Homo sapiens	95-98	
27437760-6	2017	Furthermore, vitamin K2 reduces the pro-apoptotic proteins Fas and Bax in osteoblasts, and decreases osteoclast differentiation by increasing osteoprotegerin and reducing the receptor activator of nuclear factor kappa-B ligand.	Vitamin K 2	13-23	TNF superfamily member 11	Homo sapiens	175-226